New strategy defeats cancer cells that evade chemotherapy

Multiple sclerosis patients could get better quality of life through new world-first therapy
December 3, 2018
Hepatitis C in females: Symptoms, causes, and treatment
December 4, 2018
Show all

New strategy defeats cancer cells that evade chemotherapy

NEW STRATEGY: Scientistare making the cancer cells that survive chemotherapy more aggressive so they become more vulnerable to anti-inflammatories.

New research finds a way to tackle treatment-resistant cancer cells.

The team of researchers tested this new approach in a type of lung cancer in which the cells are able to evade chemotherapy.

In fact, exposure to chemotherapy can alter the cells so much that they become very difficult to treat.

Dr. Gaetano Gargiulo, group leader at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Germany, led the recent research, which reveals a potential way around this problem.

The Journal of Experimental Medicine has published a paper on the work.

According to the World Health Organization (WHO), lung cancer is one of the most common cancer worldwide and the leading cause of death from cancer.

WHO figures for 2018 estimate that 2.09 million people are living with lung cancer and that the disease will cause 1.76 million deaths during this year.

Surviving cancer cells can change

Lung cancer is not one disease but several. The vast majority of people with lung cancer have non-small cell lung cancer, and there are several subtypes within this type.

Chemotherapies that work by stopping cells from dividing are often successful, but they can also harm healthy cells and result in side effects.

Moreover, cancer cells in very aggressive tumors usually survive the treatment and undergo profound changes in the process.

“The remaining cancer cells,” says Dr. Gargiulo, “are especially dangerous because they are altered in such a way that physicians often no longer know what type of cancer cells they are dealing with.”

As a result, it becomes very difficult to decide how best to continue the treatment.

Strategy testing in non-small cell lung cancer

Dr. Gargiulo and his team investigated this issue in a type of non-small cell lung cancer that produces an abundance of an enzyme that promotes cancer.

They used mice that they had injected with cells from this cancer subtype.

The enzyme is called Enhancer of Zeste 2 (EZH2), and it blocks several tumor suppressor genes that usually prevent uncontrolled cell division.

Clinical trials are currently underway to investigate anticancer drugs that inhibit EZH2 to restore the function of the tumor suppressor genes.

The team gave one of these drugs to the mice and observed what happened. At first, as expected, the drug stopped the tumor cells from multiplying.

However, after a while, the researchers found that an inflammation response to the treatment helped the tumors resume growth. The treatment had caused the cancer cells to become more aggressive.

 

Read on: New strategy defeats cancer cells that evade chemotherapy

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.